prog - PROG STOCK NEWS

Progenity (Nasdaq: PROG) recently presented data on its PIL Dx technology at the ACG virtual annual meeting. This ingestible capsule aims to improve the diagnosis of Small Intestinal Bacterial Overgrowth (SIBO). The presentations highlighted a study showing a 94% agreement with standard diagnostic methods, emphasizing the technology's potential to provide accurate, non-invasive testing. As Progenity progresses toward commercialization in 2021, the GI community's positive reception indicates a significant unmet need for better diagnostic tools in gastrointestinal diseases.

Progenity, Inc. (Nasdaq: PROG) has announced that two abstracts on its ingestible technologies for gastrointestinal disorders will be presented at the American College of Gastroenterology (ACG) virtual annual meeting from October 23-28, 2020. The company will showcase one oral and one poster presentation, both included in on-demand sessions and the virtual e-poster hall, with embargoed details until October 26 at 8:00 a.m. EST. Progenity aims to enhance diagnosis and treatment of gastrointestinal issues through innovative molecular testing and precision medicine.

Progenity, Inc. (Nasdaq: PROG) supports the Preeclampsia Foundation's initiative to expedite the development of biomarker tests for diagnosing preeclampsia, a serious pregnancy condition. CEO Harry Stylli emphasized the urgency of accurate testing since current methods are outdated. Progenity is advancing a novel biomarker blood test to help healthcare professionals distinguish preeclampsia from other conditions. The test aims to improve patient care and potentially reduce unnecessary hospitalizations and preterm births.

Progenity, a biotechnology firm, has been officially added to the Russell 2000 Index, effective September 18, 2020. This index tracks small-cap stocks in the U.S. equity market and is utilized by investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against it. Progenity specializes in developing molecular testing products and aims to enhance patient care through precise diagnostics and targeted therapies. This inclusion may enhance Progenity's visibility and appeal to a broader investor base.

Progenity, a biotechnology company listed on Nasdaq under the symbol PROG, announced that CEO Harry Stylli will participate in two virtual investor conferences. The first presentation will be at Baird's 2020 Global Healthcare Conference on September 9, 2020, at 12:15 p.m. ET, followed by an analyst-led group meeting at the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 12:40 p.m. ET. Live audio webcasts for both events will be available on Progenity's website, along with archived replays.

Progenity (Nasdaq: PROG) celebrates the updated guidelines from ACOG and SMFM recommending universal aneuploidy screening for pregnant patients, regardless of age. CEO Harry Stylli highlighted that this endorsement aligns with the medical community's advocacy for non-invasive prenatal testing (NIPT), specifically the Innatal Prenatal Screen, which boasts a clinical sensitivity of over 99%. This is seen as a significant step toward improving access to advanced screening options for all pregnant individuals.

Progenity, Inc. (Nasdaq: PROG) reported significant corporate updates and financial results for Q2 2020. They completed an initial public offering raising $100 million and received a $22.7 million tax refund from the CARES Act. Test volume reached 75,017, demonstrating resilience during the COVID-19 pandemic. The company also signed its first precision medicine program pharma deal, enhancing its growth prospects. Despite revenue of $17.3 million, a net loss of $53.1 million was reported, reflecting ongoing challenges in profitability.

Progenity (Nasdaq: PROG) has resolved civil and criminal investigations with the Department of Justice and the Department of Health and Human Services related to past business practices. The DOJ opted not to prosecute and instead entered into a non-prosecution agreement, highlighting Progenity's extensive cooperation and remediation efforts. The company will pay $35.8 million to settle federal claims and an additional $13.2 million for state claims. Progenity is focusing on enhancing compliance and transitioning to an in-network provider, aiming to strengthen its position in molecular testing and precision medicine.

Progenity, a biotechnology company, has priced its initial public offering (IPO) at $15.00 per share, aiming to raise approximately $100 million. The offering consists of 6,666,667 shares, all offered by Progenity, with trading expected to commence on June 19, 2020, under the ticker symbol 'PROG'. Additionally, underwriters may purchase up to 1,000,000 extra shares within 30 days. The IPO is anticipated to close on June 23, 2020, pending customary conditions. Key underwriters include Piper Sandler & Co. and Wells Fargo Securities.